Welcome to LookChem.com Sign In|Join Free
  • or

25316-40-9

Post Buying Request

25316-40-9 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Doxorubicin hydrochloride
Cas No: 25316-40-9
USD $ 2.0-2.0 / Gram 1 Gram 1 Metric Ton/Week GIHI CHEMICALS CO.,LIMITED Contact Supplier
High quality Doxorubicin hydrochloride99%
Cas No: 25316-40-9
USD $ 10.0-10.0 / Gram 10 Gram 10000 Gram/Month Shanghai Upbio Tech Co.,Ltd Contact Supplier
Factory supply Doxorubicin Hcl/Hydrochloride CAS 25316-40-9
Cas No: 25316-40-9
USD $ 100.0-100.0 / Gram 2 Gram 10 Metric Ton/Year Sinoway Industrial Co., Ltd. Contact Supplier
Doxorubicin hydrochloride Manufacturer/High quality/Best price/In stock
Cas No: 25316-40-9
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Dayang Chem (Hangzhou) Co.,Ltd. Contact Supplier
High purity doxorubicin hydrochloride with high quality and best price cas:25316-40-9
Cas No: 25316-40-9
USD $ 50.0-70.0 / Kilogram 1 Kilogram 99999 Kilogram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
CAS:25316-40-9 Doxorubicin hydrochloride
Cas No: 25316-40-9
No Data 1 Gram 100 Kilogram/Month Kono Chem Co.,Ltd Contact Supplier
Doxorubicin hydrochloride CAS NO.25316-40-9
Cas No: 25316-40-9
USD $ 1.0-3.0 / Metric Ton 1 Metric Ton 10 Metric Ton/Day Hebei yanxi chemical co.,LTD. Contact Supplier
CAS 25316-40-9 Doxorubicin hydrochloride
Cas No: 25316-40-9
USD $ 10.0-10.0 / Gram 1 Gram 10 Kilogram/Day Hubei Vanz Pharm Co.,Ltd Contact Supplier
High quality Doxorubicin hydrochloride Powder
Cas No: 25316-40-9
USD $ 10.0-12.0 / Gram 100 Gram 100000 Kilogram/Year Xi'an Quanao Biotech Co., Ltd. Contact Supplier
Adriamycin hydrochloride
Cas No: 25316-40-9
No Data No Data No Data Chemwill Asia Co., Ltd. Contact Supplier

25316-40-9 Usage

Reactivity Profile

Amines, like Doxorubicin hydrochloride, are weak chemical bases. They neutralize acids to form salts plus water. These acid-base reactions are exothermic. Amines may be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated by amines in combination with strong reducing agents, such as hydrides.

Uses

Antibacterial;DNA intercalant

Uses

Doxorubicin hydrochloride (adriamycin hydrochloride) is an antitumour agent that has been formulated as a salt to achieve higher water solubility. While the salt shares the same pharmacological properties as doxorubicin free base, its greater water solubility may offer advantages in some in vitro applications. Physicochemical properties and chromatographic behaviour will depend on whether the pH is buffered. In non-pH controlled systems the free base and salt may behave differently.

Originator

Adriblastina,Farmitalia,Italy,1971

General Description

Orange-red thin needles. Aqueous solutions yellow-orange at acid pHs, orange-red at neutral pHs, and violet blue over pH 9.

Manufacturing Process

Two 300 ml Erlenmeyer flasks, each containing 60 ml of the following culture medium for the vegetative phase, were prepared: peptone 0.6%; dry yeast 0.3%; hydrated calcium carbonate 0.2%; magnesium sulfate 0.01%; the pH after sterilization was 7.2. Sterilization has been effected by heating in autoclave to 120°C for 20 minutes. Each flask was inoculated with a quantity of mycelium of the mutant F.I.106 (the new strain thus obtained has been given the code F.I.106 of the Farmitalia microbiological collection and has been called Streptomycespeucetius var. caesius) corresponding to 1/9 of a suspension in sterile water of the mycelium of a 10 day old culture grown in a big test tube on the following medium: saccharose 2%; dry yeast 0.1%; bipotassium phosphate 0.2%; sodium nitrate 0.2%; magnesium sulfate 0.2%; agar 2%; tap water up to 100%. The flasks were then incubated at 28°C for 48 hours on a rotary shaker with a stroke of 30 mm at 220 rpm.,2 ml of a vegetative medium thus grown were used to inoculate 300 ml Erlenmeyer flasks with 60 ml of the following medium for the productive phase: glucose 6%; dry yeast 2.5%; sodium chloride 0.2%; bipotassium phosphate 0.1%; calcium carbonate 0.2%; magnesium sulfate 0.01%; ferrous sulfate 0.001%; zinc sulfate 0.001%; copper sulfate 0.001%; tap water to 100%. The glucose was previously sterilized separately at 110°C for 20 minutes. The resulting pH was 7. This was sterilized at 120°C for 20 minutes and incubated at 28°C under the same conditions by stirring, as for the vegetative media.The maximum concentration of the antibiotic was reached on the 6th day of fermentation. The quantity of adriamycin produced at this time corresponds to a concentration of 15 μg/ml.

Biological Functions

The C13 substituent of doxorubicin is hydroxymethyl, which retards the action of cytosolic aldoketoreductase and slows the conversion to the equally active, but chronically cardiotoxic, doxorubicinol.

Clinical Use

Doxorubicin is utilized either alone or in combination therapy to treat a wide range of neoplastic disorders, including hematologic cancers and solid tumors in breast, ovary, stomach, bladder, and thyroid gland. A liposomal formulation of doxorubicin is used in the treatment of AIDS-related Kaposi's sarcoma and organoplatinum-resistant ovarian cancer.

Incompatibilities

Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides

Metabolism

This contributes to the longer duration of action compared to analogues that have CH3 at this position (e.g., daunorubicin). Doxorubicin is highly lipophilic and concentrates in the liver, lymph nodes, muscle, bone marrow, fat, and skin. Elimination is triphasic, and the drug has a terminal half-life of 30 to 40 hours. The majority of an administered dose is excreted in the feces.

References

Arcamone F, et al 1998. Pharmacol Ther 76: 117–124. Grein A. 1987. Adv Appl Microbiol 32: 203–214 Zubrod CG. Historic milestones in curative chemotherapy. Seminars in Oncology 6: 490-505, 1979 Speth PAJ, et al Clinical Pharmacology and Therapeutics 41: 661-665, 1987 Cummings J, et al Cancer Chemotherapy and Pharmacology 17: 80-84, 1986 ELIOT, H., et al (1984) Biochemistry 23: 928-936. MUINDI, J. R. F., et al FEBS Lett. 172: 226-230. Russo P, et al Anticancer Research 6: 1297-1304, 1986 Tritton TR, et al Science 217: 248-250, 1982 Goormaghtigh E, et al Biochemical Pharmacology 32: 889-893, 1983 Bouma J, et al Pharmaceutisch Weekblad, Scientific Edition 8: 109-133, 1986 Benvenuto JA, et al Cancer chemotherapy by infusion, pp. 100-113, Precept Press, Chicago, 1987 Harris PA, et al Cancer Chemotherapy Reports 59: 819-825, 1975 Greene RF, et al Cancer Research 43: 3417-3421, 1983 Mooney C, et al European Journal of Cancer and Oinical Oncology 19: 1037-1038, 1983 Fassas A, et al Nouvelle Revue Fran~ise Hematologique 26: 19-24, 1984 Celio LA, et al European Journal of Clinical Pharmacology 24: 261-266, 1983 Bachur NR, et al Journal of Medicinal Chemistry 19: 651-654, 1976 Myers CE, et al In Lawn (Ed.) Anthracyclines in press, 1988 Takanashi S, et al Drug Metabolism and Disposition 4: 79-87, 1976 DiFronzo G, et al Biomedicine 19: 169-171, 1973 Mimnaugh EG, et al Biochemical Pharmacology 35: 4327-4335, 1986 Benjamin RS, et al Cancer Research 37: 1416-1420, 1977 Legha SS, Hortobagyi GN, benjamin RS. Anthracyclines. In Lokich JJ (Ed) Cancer chemotherapy by infusion, pp. 100-113, Precept Press, Chicago, 1987 Rudolph R, Journal of Clinical Oncology 5: 1116-1126, 1987 Maral RJ, et al Cancer Treatment Reports 65 (Suppl. 4): 9-18, 1981

Administration and formulation

Doxorubicin is available as a dry powder; reconstituted in water, it is most stable at a mildly acidic pH of 4, and unstable at a very acidic or basic pH[11]. When diluted in 0.9% sodium chloride or dextrose 5%, less than 5% decomposition occurred over 7 to 30 days[12]. It is stable in light at room temperature for at least 24 hours [12], although stability may be shorter in plasma and culture media[11]. Doxorubicin has been administered intravenously, intra-arterially, intraperitoneally, intrapleurally and intravesically. A bioavailability of 5% prohibits oral administration[13]. Subcutaneous, intramuscular and intrathecal application cannot be used, as severe tissue necrosis results, as in extravasation.

Mechanism of action

Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action, however, remaining not fully understood: Data pointing to the role of free radicals, and to damage of mitochondria and membranes, have modified the original hypothesis that DNA-intercalation was the sole cytotoxic mechanism. Meanwhile, the focus on plasma pharmacokinetics has been shifted towards pharmacodynamic studies, with emphasis on cellular doxorubicin concentrations in haematopoietic tissues[4], in solid tumours[5], and in cell constituents. Doxorubicin forms complexes with DNA by intercalation between base pairs. In addition, doxorubicin-iron complexes bind tightly to DNA[6]. However, contrary to intercalated doxorubicin, the doxorubicin-iron complex preserves its ability to catalyze the formation of oxygen free radicals in the presence of double-stranded DNA[6]. Thus, the doxorubicin-iron complex-driven hydroxyl radical formation can proceed in close proximity to DNA and has therefore the potential to damage DNA efficiently, especially since DNA seems to catalyze hydroxyl radical formation by this complex[7]. Hydroxyl radicals are probably involved in damaging of DNA since the generation of hydroxyl radicals by the Dox-iron complex correlates with its ability to cleave DNA[7] and also since catalase, iron chelates and hydroxyl radical scavengers are protective in this system[6]. Relatively high concentrations of hydroxyl radical scavengers were required for protection, indicating that these radicals were indeed generated in a site-specific way. Moreover, it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. Topoisomerase II causes transient double-strand breaks during the twisting of 2 double-stranded DNA helices. Singleand double-stranded DNA breaks have been documented after in vivo and in vitro treatment with doxorubicin of P388 leukaemia cells in mice[8]. Special reference must be made to observations that interference with the cell membrane alone may lead to cell death [9]. Doxorubicin binding to membranes, and particularly its covalent binding to cardiolipin, a phospholipid with 2 negatively charged phosphate head groups, has received much attention[10]. Cardiolipin is found in the inner leaflet of the mitochondrial membrane and is closely associated with electron transport mechanisms. Goormaghtigh et al. (1983) [10] have shown that doxorubicin bound to cardiolipin undergoes redox cycling, producing covalent binding of doxorubicin to cardiolipin in mitochondrial membranes. The hydrophobic nature of the chromophore of anthracyclines allows partitioning into the lipid phase, resulting in changed fluidity of the membrane. Diminished membrane fluidity is related to doxorubicin resistance. A detailed study of the mechanisms involved in doxorubicin-induced changes in membrane structure and function has not been undertaken. However, doxorubicin binds to the epidermal growth factor receptor at clinically relevant drug concentrations, and alters its function.

Shipping

UN2811 Toxic solids, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required.

General Description

Doxorubicin is available as both the conventional dosageform and a liposomal preparation, both of which are administeredby infusion. Doxorubicin HCl powder is available in10-, 20-, 50-, and 150-mg vials and is widely used in treatingvarious cancers, including leukemias, soft and bone tissuesarcomas, Wilms tumor, neuroblastoma, small cell lungcancer, and ovarian and testicular cancer.

Veterinary Drugs and Treatments

Doxorubicin is perhaps the most widely used antineoplastic agent at present in small animal medicine. It may be useful in the treatment of a variety of lymphomas, carcinomas, leukemias, and sarcomas in both the dog and cat, either alone or in combination protocols. Refer to the Dosage references or the Protocols found in the appendix for more information.

Indications

Doxorubicin is a potent antitumour agent active against a wide spectrum of malignancies, including leukaemias, sarcomas, breast cancer, small cell lung cancer and ovarian cancer. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer. Doxorubicin does not playa crucial role in the treatment of tumours that can be cured with chemotherapy, such as testicular carcinoma, nephroblastoma, Burkitt's tumour and choriocarcinoma[3]. Like most other cytostatic agents, doxorubicin is not effective in the most frequently occurring malignancies such as colorectal cancer and non-small cell lung cancer.

Potential Exposure

An antibiotic product from streptomyces, used as anticancer drug

Therapeutic Function

Cancer chemotherapy

Uses

Strong fluorescent dye intercalating into DNA. Antitumour antibiotic. Effect of adriamycin on heart mitochondrial DNA. Inhibitor of reverse transcriptase and RNA polymerase; immunosuppressive agent.

Air & Water Reactions

Water soluble.

Biological Activity

Antitumor antibiotic agent that inhibits DNA topoisomerase II. DNA intercalator that inhibits nucleic acid synthesis and induces apoptosis.

Brand name

Adriamycin (Pharmacia & Upjohn); Doxil (ALZA); Rubex (Bristol-Myers Squibb).

Mechanism of action

Liposomes are taken up selectively into tumor cells, presumably because of their persistence in the bloodstream and enhanced permeability of tumor vascular membranes. In liposomal form, the drug is protected against enzymes that generate cardiotoxic free radicals, although this form of the drug can still induce potentially fatal congestive heart failure. Clinical experience with the liposomal formulation is limited, and few studies comparing the long-term toxicity with that of conventional doxorubicin therapy have been conducted. Therefore, all precautions outlined for the use of doxorubin also are employed when the liposomal formulation is used.

Uses

Used as an antineoplastic

Waste Disposal

It is inappropriate and possibly dangerous to the environment to dispose of expired or waste pharmaceuticals by flushing them down the toilet or discarding them to the trash. Household quantities of expired or waste pharmaceuticals may be mixed with wet cat litter or coffee grounds, double-bagged in plastic, discard in trash. Larger quantities shall carefully take into consideration applicable DEA, EPA, and FDA regulations. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

Fire Hazard

Doxorubicin hydrochloride is probably combustible.

Side effects

Doxorubicin is a carcinogenic and mutagenic substance. Phlebitis is frequently observed after long-term intravenous infusion[24]. Paravasal leakage causes severe necrosis of skin and adjacent tissues, the extent of which depends on the degree of extravasation[25]. An appropriate antidote is not available. A number of agents injected locally may even worsen the necrosis; however, ice packs and 48 hours' rest may be beneficial[25]. Acute doxorubicin toxicity consists of gastrointestinal complaints and cardiac arrhythmias. Nausea and vomiting occur within 4 to 8 hours of doxorubicin administration and can only be partially controlled by antiemetic drugs. Arrhythmias and electrocardiographic changes are transient. Anaphylactoid and hypersensitivity reactions ('flare') may occur during injection, thus mimicking extravasation, but discontinuation of therapy is not necessary[26]. In long term, infusion the occurrence of acute side effects is almost completely abolished. Repeated administrations of doxorubicin bolus injections, and the resultant high doxorubicin plasma concentrations, have been associated with an increased risk of acute and late-onset cardiotoxicity. Delayed toxicity consists mainly of myelosuppression, alopecia and cardiomyopathy. At approximately 16 days after a single dose of doxorubicin the white blood cell and platelet counts reach their lowest point. Myelosuppression and alopecia are dose related, but independent of the mode of administration (i.e. peak plasma concentration). The onset of myelosuppression occurs after 7 to 10 days, and recovery at 19 to 24 days after doxorubicin administration. This side effect, although reversible, is dose limiting. Hair loss starts approximately 3 weeks after the first administration of doxorubicin; however, hair growth resumes a few weeks after the last therapy[26]. Local application of ice-packs to prevent hair loss have been of limited value. Mucositis and/or diarrhoea are noticed especially during long-term infusion regimens[24].

Overdosage

Acute overdosage with doxorubicin enhances the toxic effect of mucositis, leukopenia, and thrombocytopenia. Treatment of acute overdosage consists of treatment of the severely myelosuppressed patient with hospitalization, antimicrobials, platelet transfusions, and symptomatic treatment of mucositis. Use of hemopoietic growth factor (G-CSF, GM-CSF) may be considered. The 150 mg doxorubicin hydrochloride for injection and the 75 mL and 100 mL (2 mg/mL) doxorubicin hydrochloride injection vials are packaged as multiple dose vials and caution should be exercised to prevent inadvertent overdosage. Cumulative dosage with doxorubicin increases the risk of cardiomyopathy and resultant congestive heart failure (see WARNINGS). Treatment consists of vigorous management of congestive heart failure with digitalis preparations, diuretics, and after-load reducers such as ACE inhibitors.

Overview

Doxorubicin (DXR) is a clinically important cancer chemotherapeutic agent and, in spite of undesirable acute and long-term toxic effects, DXR remains one of the most widely used antitumor drugs because of its broad spectrum of activity[1]. DXR was first isolated in 1969[1] from Streptomyces peucetius subsp caesius ATCC 27952, a higher DXR-producing mutant strain derived from the wild-type S. peucetius ATCC 29050 strain, and is formed by C-14 hydroxylation of its immediate precursor, DNR. Although a number of organisms (including the 29050 strain) are known to produce DNR [2], S. peucetius subsp caesius is the only organism reported to produce DXR. The current production of DXR is over 225 kilograms annually due to its wide use and the fact that it is the starting point for the synthesis of numerous analogs and derivatives aimed at improving clinical cancer treatment[1]. Although DXR was discovered as a microbial metabolite, it is produced commercially by semi-synthesis from the more abundant DNR instead of by fermentation. High-DNR producing strains are available worldwide yet apparently lack the ability to make useful amounts of DXR or the DXR produced cannot easily be separated from the DNR that also is present. Consequently, the development of improved strains for DXR production is a beneficial goal since this drug is an expensive product. Doxorubicin Hydrochloride for Injection, USP, is a sterile red-orange lyophilized powder. Doxorubicin Hydrochloride Injection, USP, is a sterile parenteral, isotonic solution.

Pharmacokinetics

Absorption An intravenous bolus injection of doxorubicin produces high plasma concentrations, which fall quickly due to rapid and extensive distribution into tissues. 50 to 85% of plasma doxorubicin is bound to protein[13], independent of the absolute drug concentration in plasma, leaving 15 to 50% of the total doxorubicin and doxorubicinol as free drug. After repeated injections no accumulation in plasma occurs. Apparent volumes of distribution are in the range of 20 to 30 L/kg (1400 to 3000L)[14]. Doxorubicin does not cross the blood-brain barrier and is therefore inactive against tumours in the central nervous system[15]. Some transplacental passage has been observed, although healthy children have been born after pregnancies during which doxorubicin was administered from the first to the third trimester[16]. Negligible doxorubicin concentrations have been found in breast milk. Salivary doxorubicin concentrations are 6 to 26% of plasma concentrations during the first 75 minutes after administration[17]. Metabolism Doxorubicin is rapidly metabolized into the hydrophilic 13-hydoxy1 metabolite, doxorubicinol, and the poorly water-soluble aglycones, doxorubicinone and 7-deoxydoxorubicinone. Like doxorubicin, doxorubicinol is cytotoxic, but doxorubicinone is not[18]. Metabolism to doxorubicino1 occurs by cytoplasmatic NADPH-dependent aldoketoreductases, present in all cells, but particularly in red cells, and liver and kidney cells[18]. The non-cytotoxic aglycones are formed by an NADPH-dependent, cytochrome reductase-mediated cleavage of the amino sugar moiety in microsomes. This enzymatic reduction of doxorubicin is of paramount importance, as it finally produces the OH?-radicals, which cause extensive cell damage and cell death[19]. Elimination Doxorubicin and its catabolites are primarily excreted in the bile[20]. Over 50% is eliminated during the first transit through the liver. Cumulative faecal excretion over 7 days has been estimated at 25 to 45%[21]; no evidence for enterohepatic recirculation has been observed. Although patients often notice a reddish coloration of the urine during the first hours to days after doxorubicin administration, only 0.7 to 23% (on average, approximately 5%) of a dose has been recovered in the urine[20, 21], of which approximately two-thirds is unaltered drug. Nevertheless, doxorubicin-induced nephrotoxicity has been noted only in mice, rats, rabbits and dogs, and not in humans. The reason for this interspecies difference has not been explained, although stimulated lipid peroxidation may play a role[22]. The doxorubicin plasma concentration-time curve can be best described by a biexponentia1 model, which is characterized by a distribution half-life of less than 5 to 10 minutes, and a terminal phase elimination half-life of 30 ± 8 hours[14]. A triphasic curve with half-lives of 12 ± 8 minutes, 3.3 ± 2.2 hours and 30 ± 14 hours has also been proposed[23].

Chemical Properties

Doxorubicin is an orange to red cake-like or needle-like crystalline solid. It is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin hydrochloride is an orange-red, crystalline, hygroscopic powder that is soluble in water and slightly soluble in methanol.

Uses

Doxorubicin is an anthracycline antitumor antibiotic that inhibits DNA topoisomerase II by inducing double-stranded DNA breaks. By intercalating within DNA, doxorubicin inhibits nucleic acid synthesis and induces apoptosis by inducing the accumulation of the p53 tumor suppressor protein.[Cayman Chemical]
InChI:InChI=1/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1

25316-40-9 Well-known Company Product Price

Brand (Code)Product description CAS number Packaging Price Detail
TCI America (D4193)  Doxorubicin Hydrochloride  >95.0%(HPLC) 25316-40-9 25mg 1,490.00CNY Detail
TCI America (D4193)  Doxorubicin Hydrochloride  >95.0%(HPLC) 25316-40-9 100mg 4,480.00CNY Detail

25316-40-9Synthetic route

14-bromodaunorubicin hydrochloride
29742-67-4

14-bromodaunorubicin hydrochloride

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

Conditions
ConditionsYield
In water; dimethyl sulfoxide at 80℃; for 2h;64%
C61H69N7O18*5.7HCl

C61H69N7O18*5.7HCl

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

Conditions
ConditionsYield
With human protease plasmin In various solvent(s) at 37℃; pH=7.3; Product distribution; Enzymatic reaction;
C63H70N8O18*7.5HCl

C63H70N8O18*7.5HCl

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

Conditions
ConditionsYield
With human protease plasmin In various solvent(s) at 37℃; pH=7.3; Product distribution; Enzymatic reaction;
C69H76N8O20*6.5HCl

C69H76N8O20*6.5HCl

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

Conditions
ConditionsYield
With human protease plasmin In various solvent(s) at 37℃; pH=7.3; Product distribution; Enzymatic reaction;
daunomycin hydrochloride
23541-50-6

daunomycin hydrochloride

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 54 percent / bromine / methanol; dioxane; CHCl3 / 144 h / 0 - 5 °C
2: 64 percent / dimethylsulfoxide; H2O / 2 h / 80 °C
View Scheme
doxorubicin hydrochloride

doxorubicin hydrochloride

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

Conditions
ConditionsYield
Purification / work up;
doxorubicin

doxorubicin

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

Conditions
ConditionsYield
With 3,6-dimethyl-1,2,4,5-tetrazine In acetonitrile Reagent/catalyst;
With 3,6-dimethyl-1,2,4,5-tetrazine In acetonitrile Reagent/catalyst;
N-((R)-1-((R)-2-(((2S,3S,4S,6R)-3-hydroxy-2-methyl-6-(((1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)tetrahydro-2H-pyran-4-yl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)isonicotinamide

N-((R)-1-((R)-2-(((2S,3S,4S,6R)-3-hydroxy-2-methyl-6-(((1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)tetrahydro-2H-pyran-4-yl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)isonicotinamide

A

N-(pyridin-4-carbonyl)-D-Ala-L-Proline

N-(pyridin-4-carbonyl)-D-Ala-L-Proline

B

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

Conditions
ConditionsYield
With fibroblast activating protein In water Kinetics; Reagent/catalyst; Enzymatic reaction;
C44H42F2N4O14

C44H42F2N4O14

A

C17H15F2N3O4

C17H15F2N3O4

B

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

Conditions
ConditionsYield
With fibroblast activating protein In water Enzymatic reaction;
C47H55N5O20S2

C47H55N5O20S2

A

C21H30N4O10S3

C21H30N4O10S3

B

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

Conditions
ConditionsYield
Stage #1: C47H55N5O20S2 With triethyl ammonium acetate; triethylamine In aq. buffer at 20℃; for 2h; pH=9.5 - 9.9; Darkness;
Stage #2: With acetic acid In aq. buffer pH=8.2; Darkness;
Stage #3: In aq. buffer pH=6-7; Darkness;
C63H88BNO17S2

C63H88BNO17S2

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

Conditions
ConditionsYield
With dihydrogen peroxide for 48h;
doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

doxorubicin
23214-92-8

doxorubicin

Conditions
ConditionsYield
With triethylamine In chloroform at 25℃; for 24h; Darkness;100%
With 4 Å molecular sieves Aqueous carbonate buffer;73%
With triethylamine In dimethyl sulfoxide for 1h;
naphthalene-2-sulfonate
120-18-3

naphthalene-2-sulfonate

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

doxorubicin naphthalene-2-sulfonate
1246449-86-4

doxorubicin naphthalene-2-sulfonate

Conditions
ConditionsYield
Stage #1: doxorubicin hydrochloride With potassium tert-butylate In tetrahydrofuran at 20.2 - 21.4℃; for 1.41667h; Inert atmosphere;
Stage #2: naphthalene-2-sulfonate In tetrahydrofuran at 20℃; for 1h; Inert atmosphere;
100%
Fmoc-Phe-Lys(MMT)-PABC-PNP

Fmoc-Phe-Lys(MMT)-PABC-PNP

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

Fmoc-Phe-Lys(MMT)-PABC-Dox
847871-55-0

Fmoc-Phe-Lys(MMT)-PABC-Dox

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In 1-methyl-pyrrolidin-2-one at 20℃;99.6%
N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide
82911-69-1

N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

N-Fmoc doxorubicin

N-Fmoc doxorubicin

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 24h; Inert atmosphere; Darkness;99%
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃;80%
With N-ethyl-N,N-diisopropylamine In dichloromethane; N,N-dimethyl-formamide at 20℃; for 2h;80%
carbonic acid 4-(2,5-dioxo-3,4-bis-phenylsulfanyl-2,5-dihydro-pyrrol-1-yl)-benzyl ester 4-nitro-phenyl ester
1451073-54-3

carbonic acid 4-(2,5-dioxo-3,4-bis-phenylsulfanyl-2,5-dihydro-pyrrol-1-yl)-benzyl ester 4-nitro-phenyl ester

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

{3-hydroxy-2-methyl-6-[3,5,12-trihydroxy-3-(2-hydroxy-acetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-naphthacen-1-yloxy]-tetrahydro-pyran-4-yl}-carbamic acid 4-(2,5-dioxo-3,4-bis-phenylsulfanyl-2,5-dihydro-pyrrol-1-yl)-benzyl ester
1451073-56-5

{3-hydroxy-2-methyl-6-[3,5,12-trihydroxy-3-(2-hydroxy-acetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-naphthacen-1-yloxy]-tetrahydro-pyran-4-yl}-carbamic acid 4-(2,5-dioxo-3,4-bis-phenylsulfanyl-2,5-dihydro-pyrrol-1-yl)-benzyl ester

Conditions
ConditionsYield
With triethylamine In 1-methyl-pyrrolidin-2-one at 20℃; for 72h;99%
With triethylamine In 1-methyl-pyrrolidin-2-one at 20℃; for 72h; Darkness;99%
doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

biotinamidocaproate N-hydroxysuccinimide ester
89889-52-1

biotinamidocaproate N-hydroxysuccinimide ester

C43H54N4O14S
1401539-59-0

C43H54N4O14S

Conditions
ConditionsYield
With pyridine; dmap at 20℃; for 16h;98%
doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

trifluoroacetic acid
76-05-1

trifluoroacetic acid

adipic acid dihydrazide
1071-93-8

adipic acid dihydrazide

C33H41N5O12*2C2HF3O2

C33H41N5O12*2C2HF3O2

Conditions
ConditionsYield
In methanol at 20℃; for 5h;97%
doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

toluene-4-sulfonic acid
104-15-4

toluene-4-sulfonic acid

doxorubicin tosylate

doxorubicin tosylate

Conditions
ConditionsYield
Stage #1: doxorubicin hydrochloride With potassium tert-butylate In tetrahydrofuran at 19 - 22.4℃; for 1.91667h; Inert atmosphere;
Stage #2: toluene-4-sulfonic acid In tetrahydrofuran at 20℃; for 0.5h;
97%
C47H51N7O11S2

C47H51N7O11S2

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

C68H75N7O19S2

C68H75N7O19S2

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; under 760.051 Torr; for 16h; Inert atmosphere;97%
4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid N-succinimidyl ester
64987-85-5

4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid N-succinimidyl ester

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

doxorubicin-succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate
400647-59-8

doxorubicin-succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 12h;96%
With triethylamine In N,N-dimethyl-formamide at 20℃;
With triethylamine In N,N-dimethyl-formamide
With triethylamine In N,N-dimethyl-formamide at 20℃; pH=Ca. 8; Darkness;
doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

benzenesufonyl hydrazide
80-17-1

benzenesufonyl hydrazide

13-benzenesulfonylhydrazone-doxorubicin hydrochloride

13-benzenesulfonylhydrazone-doxorubicin hydrochloride

Conditions
ConditionsYield
In methanol at 0 - 45℃; for 16 - 240h;96%
poly(17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester of 6-(2-methacryloylamino)hexanoic acid-co-N1-(6-hydrazino-6-oxohexyl)-2-methylacrylamide-co-N-(2-hydroxypropyl)methacrylamide)

poly(17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester of 6-(2-methacryloylamino)hexanoic acid-co-N1-(6-hydrazino-6-oxohexyl)-2-methylacrylamide-co-N-(2-hydroxypropyl)methacrylamide)

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

PHPMA-AH-NH-N=DOX-co-MA-AH-chol

PHPMA-AH-NH-N=DOX-co-MA-AH-chol

Conditions
ConditionsYield
acetic acid In methanol at 25℃; for 22h;96%
C21H20N2O6

C21H20N2O6

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

C42H44N2O14

C42H44N2O14

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 1h;96%
C19H14Cl2N2O6

C19H14Cl2N2O6

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

C40H38Cl2N2O14

C40H38Cl2N2O14

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 1h;95%
With triethylamine In N,N-dimethyl-formamide at 20℃; for 1h;95%
(2,3,4-tri-O-acetyl-α-L-rhamnopyranosyl) 4-nitrophenyl carbonate
1350891-95-0

(2,3,4-tri-O-acetyl-α-L-rhamnopyranosyl) 4-nitrophenyl carbonate

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

N-(2,3,4-tri-O-acetyl-α-L-rhamnopyranosyloxycarbonyl)doxorubicin
1350892-00-0

N-(2,3,4-tri-O-acetyl-α-L-rhamnopyranosyloxycarbonyl)doxorubicin

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide94%
C59H106N2O30

C59H106N2O30

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

C82H130N2O38

C82H130N2O38

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 14h; Inert atmosphere; Darkness;94%
doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

trifluoroacetic anhydride
407-25-0

trifluoroacetic anhydride

N-Trifluoroacetyladriamycin
26295-56-7

N-Trifluoroacetyladriamycin

Conditions
ConditionsYield
With pyridine In diethyl ether at -30 - 0℃; for 3h; Schlenk technique;94%
With pyridine In diethyl ether at -20℃; for 0.5h;91%
(9H-fluoren-9-yl)methyl ((S)-1-(((S)-1-(((S)-4-amino- 1-((4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)amino)-1,4-dioxobutan-2-yl)amino)- 1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)carbamate

(9H-fluoren-9-yl)methyl ((S)-1-(((S)-1-(((S)-4-amino- 1-((4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)amino)-1,4-dioxobutan-2-yl)amino)- 1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)carbamate

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

Nα-Fmoc-Ala-Ala-Asn-PABC-doxorubicin

Nα-Fmoc-Ala-Ala-Asn-PABC-doxorubicin

Conditions
ConditionsYield
With benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide Darkness;94%
(E)-2,5-dioxopyrrolidin-1-yl 1-(cyclooct-4-en-1-yloxy)-1-oxo-5,8,11,14-tetraoxa-2-azaheptadecan-17-oate

(E)-2,5-dioxopyrrolidin-1-yl 1-(cyclooct-4-en-1-yloxy)-1-oxo-5,8,11,14-tetraoxa-2-azaheptadecan-17-oate

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

C47H62N2O18

C47H62N2O18

Conditions
ConditionsYield
With triethylamine In dimethyl sulfoxide at 20℃; for 24h; Darkness;94%
6-azidohexanoic hydrazide
1039044-92-2

6-azidohexanoic hydrazide

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

C33H40N6O11*ClH

C33H40N6O11*ClH

Conditions
ConditionsYield
With acetic acid; sodium sulfate In methanol at 20℃; for 12h; Darkness;93%
With acetic acid; sodium sulfate In methanol at 65℃; for 24h; Darkness;62.4%
With acetic acid; sodium sulfate In methanol at 65℃; for 24h;62.4%
With acetic acid In methanol
C27H25N3O14S2

C27H25N3O14S2

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

C48H49N3O22S2

C48H49N3O22S2

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 5h;93%
linolenyl hydrazide
1169394-01-7

linolenyl hydrazide

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

C45H59N3O11*ClH

C45H59N3O11*ClH

Conditions
ConditionsYield
With trifluoroacetic acid In methanol at 20℃;92%
C17H15N5O8
1596412-91-7

C17H15N5O8

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

C38H39N5O16
1596412-92-8

C38H39N5O16

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃;92%
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃;
3,4-dithiophenoylmaleimide-N-hexanoic acid

3,4-dithiophenoylmaleimide-N-hexanoic acid

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

N-(hexanamide-N-doxorubicin)-3,4-dithiophenoylmaleimide

N-(hexanamide-N-doxorubicin)-3,4-dithiophenoylmaleimide

Conditions
ConditionsYield
Stage #1: 3,4-dithiophenoylmaleimide-N-hexanoic acid With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; under 760.051 Torr; for 0.05h; Inert atmosphere;
Stage #2: doxorubicin hydrochloride In N,N-dimethyl-formamide at 20℃; under 760.051 Torr; for 6h; Inert atmosphere;
92%
doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

diprop-2-enyl N-<(4-<<4-nitrophenoxycarbonyloxy>methyl>phenyl)carbamoyl>-L-glutamate
180839-15-0

diprop-2-enyl N-<(4-<<4-nitrophenoxycarbonyloxy>methyl>phenyl)carbamoyl>-L-glutamate

N-<4-(dipropen-2-yl-L-glutamylcarbonylamino)benzyloxycarbonyl>doxorubicin

N-<4-(dipropen-2-yl-L-glutamylcarbonylamino)benzyloxycarbonyl>doxorubicin

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide for 3.5h; Ambient temperature;91.1%
doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

N-(9-fluorenylmethoxycarbonyl)-β-alanyl-L-leucyl-L-alanyl-L-leucine

N-(9-fluorenylmethoxycarbonyl)-β-alanyl-L-leucyl-L-alanyl-L-leucine

N-[N-(9-fluorenylmethoxycarbonyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]doxorubicin
274913-06-3

N-[N-(9-fluorenylmethoxycarbonyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]doxorubicin

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 2h;90%
doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

trifluoroacetic acid
76-05-1

trifluoroacetic acid

4-(4-(N-maleimido)phenyl)butyric acid hydrazide hydrochloride

4-(4-(N-maleimido)phenyl)butyric acid hydrazide hydrochloride

C41H42N4O13*C2HF3O2

C41H42N4O13*C2HF3O2

Conditions
ConditionsYield
In methanol at 20℃; for 5h;90%
cis-aconitic anhydride
6318-55-4

cis-aconitic anhydride

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

cis-aconitic anhydride doxorubicin
1425615-40-2

cis-aconitic anhydride doxorubicin

Conditions
ConditionsYield
Stage #1: doxorubicin hydrochloride With sodium hydrogencarbonate In water at 0℃;
Stage #2: cis-aconitic anhydride In 1,4-dioxane; water at 0 - 20℃; for 0.666667h; pH=8.5;
Stage #3: With hydrogenchloride In 1,4-dioxane; water
90%
With triethylamine In N,N-dimethyl-formamide at 25℃; for 24h;
With triethylamine In N,N-dimethyl-formamide
4-nitrophenyl 2-(2-(pyridin-2-yl)disulfanyl)ethyl carbonate
874302-76-8

4-nitrophenyl 2-(2-(pyridin-2-yl)disulfanyl)ethyl carbonate

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

doxorubicin 2-(pyridy-2-yldithio)ethylcarbamate
1058725-05-5

doxorubicin 2-(pyridy-2-yldithio)ethylcarbamate

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 16h; Inert atmosphere;90%
With triethylamine In dichloromethane; N,N-dimethyl-formamide at 20℃; for 12h; Darkness;87%
With triethylamine In dichloromethane; N,N-dimethyl-d6-formamide at 20℃; for 12h; Darkness;87%
N-(p-benzoic acid)-3,4-dithiophenoylmaleimide

N-(p-benzoic acid)-3,4-dithiophenoylmaleimide

doxorubicin hydrochloride
25316-40-9

doxorubicin hydrochloride

N-( p-benzamide-N-doxorubicin)-3,4-dithiophenoylmaleimide

N-( p-benzamide-N-doxorubicin)-3,4-dithiophenoylmaleimide

Conditions
ConditionsYield
Stage #1: N-(p-benzoic acid)-3,4-dithiophenoylmaleimide With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; under 760.051 Torr; for 0.05h; Inert atmosphere;
Stage #2: doxorubicin hydrochloride In N,N-dimethyl-formamide at 20℃; under 760.051 Torr; for 6h; Inert atmosphere;
90%

25316-40-9Upstream product

25316-40-9Downstream Products

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 25316-40-9